Pharmacologic management of Alzheimer disease: Part III: Nonsteroidal antiinflammatory drugs - Emerging protective evidence?

Annals of Pharmacotherapy

Volumn 33, Issue 7-8, 1999, Pages 840-849

  Flynn, Barbara L ^a,b   Theesen, Karen A ^a,c  

^a CREIGHTON UNIVERSITY   (United States)

^b St Joseph Villa Nursing Center   (United States)

^c St Joseph Center for Mental Health   (United States)

Author keywords

Alzheimer disease; Nonsteroidal antiinflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID; CORTICOSTEROID; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE;

ALZHEIMER DISEASE; AMYLOIDOSIS; ARTHRITIS; ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DRUG EFFECT; DRUG MECHANISM; DRUG RESEARCH; GASTROINTESTINAL SYMPTOM; HUMAN; META ANALYSIS; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0032791073     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.17093     Document Type: Article

References (79)

1. Wilcock GK, Harrold PL. Treatment of Alzheimer's disease: future directions. Acta Neurol Scand Suppl 1996;165(suppl):S128-36.
2. McGeer PL, McGeer EG. The inflammatory response system of brain: implications of therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 1995;21:195-218.
3. McGeer PL, McGeer EG. Anti-inflammatory drugs in the fight against Alzheimer's disease. Ann N Y Acad Sci 1996;777:213-20.
4. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factor for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996;47:425-32.
5. Haruda FD. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease (letter). Neurology 1995;45:2116.
6. McEvoy GK, ed. AHFS drug information 96. Bethesda, MD: American Society of Hospital Pharmacists, 1996:1387,1408,1417,1430,1457.
7. Heyman A, Wilkinson WE, Stafford JA, Helms MJ, Sigmon AH, Weinberg T. Alzheimer's disease: a study of epidemiological aspects. Ann Neurol 1984;15:335-41.
8. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
9. Wechsler D. Manual for the Wechsler Adult Intelligence Scale. New York: Psychological Corporation, 1955.
10. French LR, Schuman LM, Mortimer JA, Hutton JT, Boatman RA, Christians B. A case-control study of dementia of the Alzheimer's type. Am J Epidemiol 1985;121:414-21.
11. Hutton JT. Results of clinical assessment for the dementia syndrome: implications for epidemiologic studies. In: Mortimer JA, Schuman LM, eds. The epidemiology of dementia. New York: Oxford University Press, 1981:62-9.
12. Graves AB, White E, Koepsell TD, Reifler BV, van Belle G, Larson EB, et al. A case-control study of Alzheimer's disease. Ann Neurol 1990;28:766-74.
13. Diagnostic and statistical manual of mental disorders. 3rd ed., revised. Washington, DC: American Psychiatric Association, 1987.
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force of Alzheimer's Disease. Neurology 1984;34:939-44.
15. Broe GA, Henderson AS, Creasey H, McCusker E, Korten AE, Jorm AF, et al. A case-control study of Alzheimer's disease in Australia. Neurology 1990;40:1698-707.
16. Wechsler D. A standardized memory scale for clinical use. J Psychol 1945;19:87-95.
17. Goldstein KH, Sheerer M. Tests of abstract and concrete behavior. In: Weider A, ed. Contributions to medical psychology, vol 2. New York: Ronald Press, 1953.
18. Benton AL, Hamsher K. Multilingual aphasia examination. Iowa City, IA: University of Iowa, 1976.
19. Li G, Shen YC, Li YT, Chen CH, Zhau YW, Silverman JM. A case-control study of Alzheimer's disease in China. Neurology 1992;42:1481-8.
20. Differential Diagnosis of Dementia Scale. Geneva: World Health Organization, Division of Mental Health.
21. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43:1609-11.
22. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-64.
23. Kaplan EF, Goodglass H, Weintraub S. The Boston Naming Test. Boston: E Kaplan & H Goodglass, 1978.
24. Vamey NR, Spreen O. Contributions to neuropsychological assessment. In: Benton AL, Hamsher K, eds. New York: Psychological Corporation, 1981.
25. The Canadian Study of Health and Aging: risk factors for Alzheimer's disease in Canada. Neurology 1994;44:2073-80.
26. Teng EL, Chui HC. The Modified Mini-Mental State (3MS) Examination. J Clin Psychiatry 1987;48:314-8.
27. Breitner JCS, Gau BA, Welsh KA, Plassman BL, McDonald WM, Helms MJ, et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 1994;44:227-32.
28. Brandt J, Spencer M, Folstein M. The telephone interview for cognitive status. Neuropsychiatry Neuropsychol Behav Neurol 1988;1:111-7.
29. Silverman JM, Breitner JCS, Mohs RC, Davis KL. Reliability of the family history method in genetic studies of Alzheimer's disease and related dementias. Am J Psychiatry 1986;143:1279-82.
30. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995;45:51-5.
31. Gollin ES. Developmental studies of visual recognition of incomplete objects. Percept Mot Skills 1960;11:289-98.
32. Moss MB, Albert MD, Butters N, Payne M. Differential patterns of memory loss among patients with Alzheimer's disease, Huntington's disease and alcoholic Korsakoff's syndrome. Arch Neurol 1986;43:239-46.
33. De Renzi E, Vignolo LA. The Token Test: a sensitive test to detect disturbances in aphasia. Brain 1962;85:665-78.
34. 2 blocking drugs. Neurobiol Aging 1995;16:523-30.
35. Andersen K, Launer LJ, Ott A, Hoes AW, Breteler MMB, Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology 1995;45:1441-5.
36. Copeland JRM, Kellerer MJ, Kellett JM, Gourlay AJ, Gurland BJ, Fleiss JL, et al. A semi-structured clinical interview for the assessment and diagnosis of mental state in the elderly: the Geriatric Mental State Schedule. Psychol Med 1976;6:439-49.
37. Berg L. Clinical Dementia Rating (CDR). Psychopharmacol Bull 1988;25:637-9.
38. Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Verma S, et al. CAMDEX: a standardised instrument for the diagnosis of mental disorders in the elderly with special reference to the early detection of dementia. Br J Psychiatry 1986;149:698-709.
39. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997;48:626-32.
40. Shock N, Greulich R, Andres R, Arenberg D, Costa PT Jr, Lakatta EG, et al. Normal human aging: the Baltimore Longitudinal Study of Aging (NIH Pub. No. 84-2450). Washington, DC: US Government Printing Office, 1984.
41. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile changes in the cerebral gray matter of elderly subjects. Br J Psychiatry 1968;114:797-811.
42. Grober E, Buschke H. Genuine memory deficits in dementia. Dev Neuropsychol 1987;3:13-6.
43. Army Individual Test Battery. Manual of directions and scoring. Washington, DC: War Department, Adjuvant General's Office, 1944.
44. Rouleau I, Salmon DP, Butters N, Kennedy C, McGuire K. Quantitative and qualitative analyses of clock drawings in Alzheimer's and Huntington's disease. Brain Cogn 1992;18:70-87.
45. Benton AL. Differential behavioral effects in frontal lobe disease. Neuropsychologia 1968;6:53-60.
46. Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol 1982;37:328-9.
47. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385-401.
48. Nelson HE, O'Connell A. Dementia: the estimation of pre-morbid intelligence using the New Adult Reading Test. Cortex 1978;14:234-44.
49. Wilkinson IM, Graham-White J. Psychogeriatric Dependency Rating Scales (PGDRS): a method of assessment for use by nurses. Br J Psychiatry 1980;137:558-65.
50. Kukull WA, Larson EB, Stergachis A, McCormick WC, Bowen JD, Teri L, et al. Non-steroidal anti-inflammatory drug use and risk of Alzheimer's disease (abstract). Neurology 1994;44(suppl 2):A237.
51. Saag KG, Rubenstein LM, Chrischilles EA, Wallace RB. Nonsteroidal antiinflammatory drugs and cognitive decline in the elderly. J Rheumatol 1995;22:2142-7.
52. Coroni-Huntley J, Brock DW, Ostfeld AM, Taylor JO, Wallace RB, eds. National Institute of Aging. Established Populations for Epidemiologic Studies of the Elderly: resource data book. Bethesda, MD: National Institutes of Health, 1986.
53. Pfeifer E. A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc 1975;23:433-41.
54. Rozzini R, Ferrucci L, Losonczy K, Havlik RJ, Guralnik JM. Protective effect of chronic NSAID use on cognitive decline in older persons. J Am Geriatr Soc 1996;44:1025-9.
55. Hanlon JT, Schmader KE, Landerman LR, Horner RD, Fillenbaum GG, Pieper CF, et al. Relation of prescription nonsteroidal antiinflammatory drug use to cognitive function among community-dwelling elderly. Ann Epidemiol 1997;7:87-94.
56. May FE, Moore MT, Stewart RB, Hale WE. Lack of association of non-steroidal anti-inflammatory drug use and cognitive function in elderly patients. Gerontology 1992;38:275-9.
57. Wysenbeek AJ, Klein Z, Nakar S, Mane R. Assessment of cognitive function in elderly patients treated with naproxen. A prospective study. Clin Exp Rheumatol 1988;6:399-400.
58. Bruce-Jones PNE, Crome P, Kalra L. Indomethacin and cognitive function in elderly volunteers. Br J Clin Pharmacol 1994;38:45-51.
59. Fourrier A, Letenneur L, Be'gaud B, Dartigues JF. Nonsteroidal antiinflammatory drug use and cognitive function in the elderly: inconclusive results from a population-based cohort study. J Clin Epidemiol 1996;49:1201.
60. Johnson AG, Quinn DI, Day RO. Non-steroidal anti-inflammatory drugs: prescribing for the elderly. Med J Aust 1995;163:155-8.
61. Polisson R. Nonsteroidal anti-inflammatory drugs: practical and theoretical considerations in their selection. Am J Med 1996;100(suppl 2A): 31S-6S.
62. F-D-C Reports. SB Relafen promotion on COX-2 selectivity withdrawn following DDMAC letter. Feb. 24, 1997; vol. 59, issue 8.
63. Bjorkman DJ. Nonsteroidal anti-inflammatory drug-induced gastrointestinal injury. Am J Med 1996;101(suppl 1A):25S-32S.
64. Roth SH. NSAID gastropathy: a new understanding. Arch Intern Med 1996;156:1623-8.
65. Stucki G, Johannesson M, Liang MH. Use of misoprostol in the elderly. Drugs Aging 1996;2:84-8.
66. Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996:1459-85.
67. Lewis DA, Smith RE. Steroid-induced psychiatric syndromes. J Affect Disord 1983;5:319-32.
68. Mallet L, Kuyumjian J. Indomethacin-induced behavioral changes in an elderly patient with dementia. Ann Pharmacother 1998;32:201-3.
69. Beard CM, Waring SC, O'Brien PC, Kurland LT, Kokmen E. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: a case-control study in Rochester, Minnesota, 1980 through 1984. Mayo Clin Proc 1998;73:951-5.
70. Pennisi E. Building a better aspirin. Science 1998;280:1191-2.
71. Alzheimer's and antiinflammatories. Harv Womens Health Watch 1998;5(8):7.
72. Mackenzie IR, Munoz DG. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology 1998;50:986-90.
73. O'Banion MK, Chang JW, Coleman PD. Decreased expression of prostaglandin G/H synthase-2 (PGHS-2) in Alzheimer's disease brain. Adv Exp Med Biol 1997;407:171-7.
74. Jorm AF. Alzheimer's disease: risk and protection. Med J Aust 1997;167:443-6.
75. Scherder EJ, Bouma A. Is decreased use of analgesics in Alzheimer disease due to a change in the affective component of pain? Alzheimer Dis Assoc Disord 1997;11:171-4.
76. Zhang W, Johnson BR, Bjornsson TD. Pharmacologic inhibition of transglutaminase-induced cross-linking of Alzheimer's amyloid beta-peptide. Life Sci 1997;60(25):2323-32.
77. Doraiswamy PM, Bieber F, Kaiser L, Krishnan KR, Reuning-Scherer J, Gulanski B. The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials. Neurology 1997;48:1511-7.
78. Tocco G, Freire-Moar J, Schreiber SS, Sakhi SH, Aisen PS, Pasinetti GM. Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease. Exp Neurol 1997;144:339-49.
79. Lieb K, Fiebich BL, Hull M, Berger M, Bauer J. Potent inhibition of interleukin-6 expression in a human astrocytoma cell line by tenidap. Cell Tissue Res 1997;228:251-7.